{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,5]],"date-time":"2026-03-05T15:01:30Z","timestamp":1772722890284,"version":"3.50.1"},"reference-count":28,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bioorganic & Medicinal Chemistry Letters"],"published-print":{"date-parts":[[2022,9]]},"DOI":"10.1016\/j.bmcl.2022.128876","type":"journal-article","created":{"date-parts":[[2022,7,3]],"date-time":"2022-07-03T20:07:26Z","timestamp":1656878846000},"page":"128876","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"special_numbering":"C","title":["Discovery of novel polyamide-pyrrolobenzodiazepine hybrids for antibody-drug conjugates"],"prefix":"10.1016","volume":"72","author":[{"given":"Joshua D.","family":"Thomas","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aleksandr V.","family":"Yurkovetskiy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mao","family":"Yin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Natalya D.","family":"Bodyak","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dmitry R.","family":"Gumerov","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shuyi","family":"Tang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eoin","family":"Kelleher","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brian D.","family":"Jones","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marina","family":"Protopopova","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"LiuLiang","family":"Qin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alex","family":"Uttard","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Damon R.","family":"Demady","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Timothy B.","family":"Lowinger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"7","key":"10.1016\/j.bmcl.2022.128876_b0005","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1056\/NEJMoa1914510","article-title":"Trastuzumab Deruxtecan in Previously Treated HER2-Positive Breast Cancer","volume":"382","author":"Modi","year":"2020","journal-title":"N Engl J Med."},{"issue":"2","key":"10.1016\/j.bmcl.2022.128876_b0010","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1002\/anie.201510610","article-title":"From Anthramycin to Pyrrolobenzodiazepine (PBD)-Containing Antibody-Drug Conjugates (ADCs)","volume":"56","author":"Mantaj","year":"2017","journal-title":"Angew Chem Int Ed Engl."},{"issue":"8","key":"10.1016\/j.bmcl.2022.128876_b0015","doi-asserted-by":"crossref","first-page":"1455","DOI":"10.1182\/blood-2013-03-491506","article-title":"SGN-CD33A: a novel CD33-targeting antibody-drug conjugate using a pyrrolobenzodiazepine dimer is active in models of drug-resistant AML","volume":"122","author":"Kung Sutherland","year":"2013","journal-title":"Blood."},{"issue":"302","key":"10.1016\/j.bmcl.2022.128876_b0020","doi-asserted-by":"crossref","first-page":"302ra136","DOI":"10.1126\/scitranslmed.aac9459","article-title":"A DLL3-targeted antibody-drug conjugate eradicates high-grade pulmonary neuroendocrine tumor-initiating cells in vivo","volume":"7","author":"Saunders","year":"2015","journal-title":"Sci Transl Med."},{"issue":"7","key":"10.1016\/j.bmcl.2022.128876_b0025","doi-asserted-by":"crossref","first-page":"1256","DOI":"10.1021\/bc400217g","article-title":"A potent anti-CD70 antibody-drug conjugate combining a dimeric pyrrolobenzodiazepine drug with site-specific conjugation technology","volume":"24","author":"Jeffrey","year":"2013","journal-title":"Bioconjug Chem."},{"issue":"10","key":"10.1016\/j.bmcl.2022.128876_b0030","doi-asserted-by":"crossref","first-page":"2176","DOI":"10.1158\/1535-7163.MCT-17-0982","article-title":"Antitumor Activity of MEDI3726 (ADCT-401), a Pyrrolobenzodiazepine Antibody-Drug Conjugate Targeting PSMA, in Preclinical Models of Prostate Cancer","volume":"17","author":"Cho","year":"2018","journal-title":"Mol Cancer Ther."},{"key":"10.1016\/j.bmcl.2022.128876_b0035","first-page":"1","article-title":"Antibody-drug conjugates (ADCs) delivering pyrrolobenzodiazepine (PBD) dimers for cancer therapy","author":"Hartley","year":"2020","journal-title":"Expert Opin Biol Ther."},{"key":"10.1016\/j.bmcl.2022.128876_b0040","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.ddtec.2018.10.004","article-title":"Use of pyrrolobenzodiazepines and related covalent-binding DNA-interactive molecules as ADC payloads: Is mechanism related to systemic toxicity?","volume":"30","author":"Jackson","year":"2018","journal-title":"Drug Discov Today Technol."},{"issue":"8","key":"10.1016\/j.bmcl.2022.128876_b0045","doi-asserted-by":"crossref","first-page":"1870","DOI":"10.1158\/1535-7163.MCT-16-0184","article-title":"A New Class of Antibody-Drug Conjugates with Potent DNA Alkylating Activity","volume":"15","author":"Miller","year":"2016","journal-title":"Mol Cancer Ther."},{"issue":"17","key":"10.1016\/j.bmcl.2022.128876_b0050","doi-asserted-by":"crossref","first-page":"2455","DOI":"10.1016\/j.bmcl.2019.07.031","article-title":"Design, synthesis and evaluation of novel, potent DNA alkylating agents and their antibody-drug conjugates (ADCs)","volume":"29","author":"Reid","year":"2019","journal-title":"Bioorg Med Chem Lett."},{"issue":"4","key":"10.1016\/j.bmcl.2022.128876_b0055","doi-asserted-by":"crossref","DOI":"10.3390\/cancers12041029","article-title":"A Novel Antibody-Drug Conjugate (ADC) Delivering a DNA Mono-Alkylating Payload to Chondroitin Sulfate Proteoglycan (CSPG4)-Expressing Melanoma","volume":"12","author":"Hoffmann","year":"2020","journal-title":"Cancers (Basel)."},{"issue":"3","key":"10.1016\/j.bmcl.2022.128876_b0060","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1021\/acsmedchemlett.0c00578","article-title":"DNA-Model-Based Design and Execution of Some Fused Benzodiazepine Hybrid Payloads for Antibody-Drug Conjugate Modality","volume":"12","author":"Sivaprakasam","year":"2021","journal-title":"ACS Med Chem Lett."},{"issue":"18","key":"10.1016\/j.bmcl.2022.128876_b0065","doi-asserted-by":"crossref","first-page":"5442","DOI":"10.1021\/jm051199z","article-title":"Design, synthesis, and biophysical and biological evaluation of a series of pyrrolobenzodiazepine-poly(N-methylpyrrole) conjugates","volume":"49","author":"Wells","year":"2006","journal-title":"J Med Chem."},{"issue":"12","key":"10.1016\/j.bmcl.2022.128876_b0070","doi-asserted-by":"crossref","first-page":"3780","DOI":"10.1016\/j.bmcl.2011.04.054","article-title":"Novel C8-linked pyrrolobenzodiazepine (PBD)-heterocycle conjugates that recognize DNA sequences containing an inverted CCAAT box","volume":"21","author":"Brucoli","year":"2011","journal-title":"Bioorg Med Chem Lett."},{"issue":"12","key":"10.1016\/j.bmcl.2022.128876_b0075","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1038\/ja.2016.43","article-title":"DNA sequence-selective C8-linked pyrrolobenzodiazepine-heterocyclic polyamide conjugates show anti-tubercular-specific activities","volume":"69","author":"Brucoli","year":"2016","journal-title":"J Antibiot (Tokyo)."},{"issue":"16","key":"10.1016\/j.bmcl.2022.128876_b0080","doi-asserted-by":"crossref","first-page":"6339","DOI":"10.1021\/jm4001852","article-title":"An extended pyrrolobenzodiazepine-polyamide conjugate with selectivity for a DNA sequence containing the ICB2 transcription factor binding site","volume":"56","author":"Brucoli","year":"2013","journal-title":"J Med Chem."},{"issue":"5","key":"10.1016\/j.bmcl.2022.128876_b0085","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1021\/jm001064n","article-title":"Design, synthesis, and evaluation of a novel pyrrolobenzodiazepine DNA-interactive agent with highly efficient cross-linking ability and potent cytotoxicity","volume":"44","author":"Gregson","year":"2001","journal-title":"J Med Chem."},{"issue":"2","key":"10.1016\/j.bmcl.2022.128876_b0090","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1021\/ol9026599","article-title":"DBU catalysis of N, N'-carbonyldiimidazole-mediated amidations","volume":"12","author":"Larrivee-Aboussafy","year":"2010","journal-title":"Org Lett."},{"issue":"6","key":"10.1016\/j.bmcl.2022.128876_b0095","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1158\/1535-7163.MCT-16-0021","article-title":"A New Triglycyl Peptide Linker for Antibody-Drug Conjugates (ADCs) with Improved Targeted Killing of Cancer Cells","volume":"15","author":"Singh","year":"2016","journal-title":"Mol Cancer Ther."},{"issue":"4","key":"10.1016\/j.bmcl.2022.128876_b0100","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1021\/bc025536j","article-title":"Cathepsin B-labile dipeptide linkers for lysosomal release of doxorubicin from internalizing immunoconjugates: model studies of enzymatic drug release and antigen-specific in vitro anticancer activity","volume":"13","author":"Dubowchik","year":"2002","journal-title":"Bioconjug Chem."},{"issue":"8","key":"10.1016\/j.bmcl.2022.128876_b0105","doi-asserted-by":"crossref","first-page":"1576","DOI":"10.1158\/1535-7163.MCT-16-0825","article-title":"Preclinical Evaluation of MEDI0641, a Pyrrolobenzodiazepine-Conjugated Antibody-Drug Conjugate Targeting 5T4","volume":"16","author":"Harper","year":"2017","journal-title":"Mol Cancer Ther."},{"issue":"3","key":"10.1016\/j.bmcl.2022.128876_b0110","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1158\/1535-7163.MCT-17-0940","article-title":"A DNA-Interacting Payload Designed to Eliminate Cross-Linking Improves the Therapeutic Index of Antibody-Drug Conjugates (ADCs)","volume":"17","author":"Miller","year":"2018","journal-title":"Mol Cancer Ther."},{"issue":"1","key":"10.1016\/j.bmcl.2022.128876_b0115","article-title":"Antibody Conjugates-Recent Advances and Future Innovations","volume":"9","author":"Leung","year":"2020","journal-title":"Antibodies (Basel)."},{"issue":"7","key":"10.1016\/j.bmcl.2022.128876_b0120","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1038\/nbt.3212","article-title":"Reducing hydrophobicity of homogeneous antibody-drug conjugates improves pharmacokinetics and therapeutic index","volume":"33","author":"Lyon","year":"2015","journal-title":"Nat Biotechnol."},{"issue":"9","key":"10.1016\/j.bmcl.2022.128876_b0125","doi-asserted-by":"crossref","first-page":"741","DOI":"10.2174\/1568026619666190401112517","article-title":"Potentiation of PBD Dimers by Lipophilicity Manipulation","volume":"19","author":"Cailleau","year":"2019","journal-title":"Curr Top Med Chem."},{"issue":"22","key":"10.1016\/j.bmcl.2022.128876_b0130","doi-asserted-by":"crossref","first-page":"6463","DOI":"10.1016\/j.bmcl.2009.09.012","article-title":"Synthesis of a novel C2\/C2'-aryl-substituted pyrrolo[2,1-c][1,4]benzodiazepine dimer prodrug with improved water solubility and reduced DNA reaction rate","volume":"19","author":"Howard","year":"2009","journal-title":"Bioorg Med Chem Lett."},{"issue":"2","key":"10.1016\/j.bmcl.2022.128876_b0135","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1016\/j.taap.2013.09.003","article-title":"Preclinical safety profile of trastuzumab emtansine (T-DM1): mechanism of action of its cytotoxic component retained with improved tolerability","volume":"273","author":"Poon","year":"2013","journal-title":"Toxicol Appl Pharmacol."},{"issue":"5","key":"10.1016\/j.bmcl.2022.128876_b0140","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1158\/1535-7163.MCT-16-0641","article-title":"Modulating Therapeutic Activity and Toxicity of Pyrrolobenzodiazepine Antibody-Drug Conjugates with Self-Immolative Disulfide Linkers","volume":"16","author":"Pillow","year":"2017","journal-title":"Mol Cancer Ther."}],"container-title":["Bioorganic & Medicinal Chemistry Letters"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960894X22003523?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960894X22003523?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,18]],"date-time":"2025-10-18T07:47:01Z","timestamp":1760773621000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0960894X22003523"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9]]},"references-count":28,"alternative-id":["S0960894X22003523"],"URL":"https:\/\/doi.org\/10.1016\/j.bmcl.2022.128876","relation":{},"ISSN":["0960-894X"],"issn-type":[{"value":"0960-894X","type":"print"}],"subject":[],"published":{"date-parts":[[2022,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Discovery of novel polyamide-pyrrolobenzodiazepine hybrids for antibody-drug conjugates","name":"articletitle","label":"Article Title"},{"value":"Bioorganic & Medicinal Chemistry Letters","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bmcl.2022.128876","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"128876"}}